# A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

> **NCT07736001** · NA · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Tumor Patients

## Interventions

- **DRUG:** Trilaciclib and Topoisomerase I inhibitor type ADC drugs

## Key facts

- **NCT ID:** NCT07736001
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736001, "A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*